Pacific Biosciences of California (NASDAQ:PACB) and Asuragen, a molecular diagnostics company announce clinical research collaboration to develop molecular assays based on PacBio’s Single Molecule, Real-Time (SMRT) Sequencing technology combined with Asuragen’s AmplideX PCR technology.
The initial focus of the collaboration will be on research in support of assay development for the carrier screening market.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.